Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

The Global Market for Hormonal Contraceptives and Infertility Drugs, 2005-2012

Published by: Spectra Intelligence

Published: Jan. 1, 2006 - 109 Pages


Table of Contents



List of Tables

List of Figures

Executive Summary

Objectives of the Report

Research Methodology

Chapter 1 Introduction to Reproductive Medicine

Ageing, Lifestyle Issues, and Reproductive Health

Elective Infertility - Contraception

The Birth of Contraception

Inducing Infertility via Ovulation Suppression

Combined Oral Contraceptives

Fertility Disorders

Assisted Conception

Chapter 2 Hormonal Contraceptives and Infertility Drug Markets

Reproductive Medicine Market Overview

Market Analysis: Contraception and Infertility
Hormonal Contraception
Contraceptive Formulations
Combined Oestrogen-Progestogen Contraceptives

Progestogen-Only Contraceptives

Product Market for Hormonal Contraceptives

Janssen-Cilag/Ortho-McNeil/Johnson & Johnson

Key Product and Portfolio Review

Sales Estimates and Product Market Outlook

Organon/Akzo Nobel

Key Product and Portfolio Review

Pipeline Focus

EMM 310066

Male Contraception - Organon/Schering

Sales Estimates and Product Market Outlook

Pharmacia/Pfizer

Key Product and Portfolio Review

Sales Estimates and Product Market Outlook

Schering/Berlex

Key Product and Portfolio Review

Pipeline Focus


Yaz

Contraceptive Patch

E2/DNG Pill

Male Contraception

Sales Estimates and Product Market Outlook

Wyeth

Key Product and Portfolio Review

Sales Estimates and Product Market Outlook

Barr Laboratories

Key Product and Portfolio Review

Pipeline Focus

Sales Estimates and Product Market Outlook

Promising Contraceptives in Research and Development

Male Contraception

University of Washington/National Institute of Child Health and Human

Development, USA

Miglustat

Nestorone Gel

Future Considerations and Outlook for the Contraceptive Product Market

Infertility Pharmacotherapeutics
Pharmacotherapies for Infertility
Mechanism of Action of Infertility Pharmacotherapeutics

Product Market Analysis for Infertility Pharmacotherapeutics

AstraZeneca

Key Product and Portfolio Review

Sales Estimates and Product Market Outlook

Ferring

Key Product and Portfolio Review

Pipeline Focus

Sales Estimates and Product Market Outlook

Organon

Key Product and Portfolio Review

Pipeline Focus

Sales Estimates and Product Market Outlook

Serono

Key Product and Portfolio Review

Pipeline Focus

Sales Estimates and Product Market Outlook

Future Considerations and Market Insights for Infertility Pharmacotherapeutics

Promising Infertility Drugs in Research and Development

Novel Female Infertility Pharmacotherapeutics

Vitropin - Vitro Diagnostics

PV903 - GroPep

Novel Male Infertility Pharmacotherapeutics

BIO316 - Enhance Biotech/Bioaccelerate

Menevit - Repromed, University of Adelaide

Commercial Prospects for Infertility Drugs

Chapter 3 Drugs in Research and Development

Contraception
Research and Development Overview
Infertility
Research and Development Overview
Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining

Reproductive Medicine: Contraception and Infertility

Therapy Area Forecasts

Market Share of Reproductive Medicine Therapy Areas

Comparative Analysis: Product Sales

Prospect Mining

Contraception

Infertility

Therapy Area Forecasts: 2012 and 2020

Chapter 5 Report Synopsis

Contraception - Key Data Points

Infertility - Key Data Points

Reference Sources

List of Tables

Table 1.1 Global Prevalence Rates of Oral Contraceptive Use

Table 1.2 Popular Combined Oral Contraceptives, 2005

Table 1.3 Biological Causes of Infertility

Table 1.4 Assisted Conception Techniques

Table 2.1 Estimated Global Sales (US$) & Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2004-2012

Table 2.2 Selection of Contraceptives Segmented by Formulation and Delivery Route

Table 2.3 Johnson & Johnson’s Hormonal Contraceptive Product Portfolio, 2005

Table 2.4 Estimated Sales (US$) and Annual Growth (%) of Ortho-McNeil/ Johnson & Johnson’s Hormonal Contraceptive Portfolio, 2005-2012

Table 2.5 Organon/Akzo Nobel’s Hormonal Contraceptive Product Portfolio, 2005

Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Organon/Akzo Nobel’s Hormonal Contraceptive Portfolio, 2005-2012

Table 2.7 Pfizer’s Hormonal Contraceptive Product Portfolio, 2005

Table 2.8 Estimated Sales (US$) and Annual Growth (%) of Pfizer’s Hormonal Contraceptive Portfolio, 2005-2012

Table 2.9 Schering/Berlex’ Hormonal Contraceptive Product Portfolio, 2005

Table 2.10 Schering/Berlex’ Pipeline Contraceptive Candidates, 2005

Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Schering/Berlex’ Hormonal Contraceptive Portfolio, 2005-2012

Table 2.12 Wyeth’s Hormonal Contraceptive Product Portfolio, 2005

Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Wyeth’s Hormonal Contraceptive Portfolio, 2005-2012

Table 2.14 Barr’s Hormonal Contraceptive Product Portfolio, 2005

Table 2.15 Estimated Sales (US$) and Annual Growth (%) of Barr’s Hormonal Contraceptive Portfolio, 2005-2012

Table 2.16 Pipeline Hormonal Contraceptives, 2005

Table 2.17 Pharmacotherapies for Infertility, 2005

Table 2.18 AstraZeneca’s Hormonal Infertility Product Portfolio, 2005

Table 2.19 Estimated Global Sales (US$) and Annual Growth (%) of AstraZeneca’s Hormonal Infertility Products, 2005-2012

Table 2.20 Ferring’s Infertility Product Portfolio, 2005

Table 2.21 Estimated Global Sales (US$) and Annual Growth (%) of Ferring’s Infertility Drugs, 2005-2012

Table 2.22 Organon’s Hormonal Infertility Product Portfolio, 2005

Table 2.23 Estimated Global Sales (US$) and Annual Growth (%) of Organon’s Hormonal Infertility Products, 2005-2012

Table 2.24 Serono’s Hormonal Infertility Product Portfolio, 2005

Table 2.25 Estimated Global Sales (US$) and Annual Growth (%) of Serono’s Hormonal Infertility Products, 2005-2012

Table 2.26 Drugs in Research and Development for Infertility, 2005

Table 3.1 Female Oral Contraceptives in Development, 2005

Table 3.2 Nonoral Female Contraceptives in Development, 2005

Table 3.3 Male Contraceptives in Development, 2005

Table 3.4 Drugs in Development for Infertility, 2005

Table 4.1 Global Drug Market for Hormonal Contraception and Infertility (US$m), 2004-2012

Table 4.2 Therapy Area Forecasts for Hormonal Contraceptives and Infertility Drugs, 2012 & 2020

List of Figures

Figure 1.1 Lifestyle Disorder Characteristics Associated with Contraception

Figure 1.2 Lifestyle Factors Affecting Fertility

Figure 2.1 Estimated Sales (US$) and Forecasts of Hormonal Contraceptives and Infertility Drug Sectors, 2004-2012

Figure 2.2 Estimated Global Market Share for Hormonal Contraceptives and Infertility Drug Sectors, 2005 & 2012

Figure 4.1 Hormonal Contraceptive and Infertility Therapy Area Forecasts, 2005 & 2012 (US$m)

Figure 4.2 Market Share of Hormonal Contraception and Infertility Therapy Areas, 2005 & 2012

Figure 4.3 Comparative Analysis of Leading Contraceptives and Infertility Drug Products, 2004-2012 (US$m)

Figure 4.4 Key Contraception Prospects in the Development Pipeline, 2005

Figure 4.5 Key Infertility Drug Prospects in the Development Pipeline, 2005

Abstract

Drugs in reproductive medicine are evolving into highly sophisticated products with multifunctional pharmacological properties and clinical utilities. Novel contraceptive formulations with low side-effect profiles are providing women with flexible birth-control and menstrual management options whilst also offering secondary indications to treat coexisting endocrinological and gynaecological disorders. Furthermore, the increasing global prevalence of infertility is driving R&D to offer novel drug solutions to improve or restore male- and female-factor infertility, optimize fertilization and embryo implantation, and reduce miscarriage. Recent advances in administering and formulating hormone-based drugs is enabling a revolution in contraception and infertility treatments. Over the next decade, the market for hormonal contraceptives and infertility drugs is predicted to expand considerably through innovation, new and expanding markets, and high-value prospects that importantly offer novel solutions to unmet needs and demands of patients who wish to modulate or enhance fertility. The current mature market for hormonal contraceptives and infertility drugs is estimated at US$7.1 billion but is forecast to increase 40% to US$9.9 billion by 2012. This report provides a detailed analysis of the global market for hormonal contraceptives and infertility drugs highlighting strategies for product extension and reformulation, sales forecasts to 2012 for leading products, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into sector performance, which may enable the reader to make key assumptions about future markets and prospects.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008